[share title=”Title” facebook=”true” twitter=”true” google_plus=”true” linkedin=”true” pinterest=”true” reddit=”true” email=”true”]Takeda Pharmaceuticals Inc. was hit with a $2.3 million verdict on Thursday after a Philadelphia jury concluded that the diabetes drug Actos had been a significant cause of a retired Pennsylvania teacher’s bladder cancer and that the man’s doctor had been inadequately warned about the risks.
The jury returned a verdict after a little more than a day of deliberation, awarding John Kristufek $318,000 in past medical expenses plus $2 million in noneconomic damages in the second successful bid by plaintiffs in the Philadelphia County Court.
The jury also opened the door for punitive damages against the company by finding that Takeda had acted with reckless disregard for patients in its development and marketing of the drug. John Kristufek, a resident of Butler County in western Pennsylvania, filed suit in July 2012 alleging that he was diagnosed with bladder cancer in 2008 after using the drug for about three years.
The verdict comes after nearly a month of testimony in the case. Kristufek alleged that Takeda’s efforts to obscure the drug’s association with bladder cancer had left his prescribing physician unaware of the risks until shortly after he was forced to have his bladder removed entirely in July 2011.
If you or someone you know has experienced harm from the Actos drug , contact Houssiere, Durant & Houssiere, LLP at 888-881-8100 or fill out the “Contact Us” form on our home page, no obligation consultation to learn your rights. You may be eligible for compensation, though there may be a time limit to file a claim.